米力农在儿童肺炎并心力衰竭的治疗应用

Milrinone in the Treatment of Children with Pneumonia and Heart Failure

目的探讨米力农在儿童肺炎并心力衰竭的治疗应用疗效。方法根据随机数字表法将方便选取2017年1月—2018年2月90例儿童肺炎并心力衰竭患儿分成两组。对照组给予常规治疗方案治疗,观察组则给予常规治疗方案联合米力农治疗,比较效果。结果观察组儿童肺炎并心力衰竭治疗转归效果44例(97.78%)高于对照组31例(68.89%)(χ^2=13.520,P<0.05);观察组呼吸恢复平稳时间、消除烦躁时间、心率稳定时间、肺部啰音消失时间、肝脏缩小时间(1.43±0.21)、(8.13±0.21)、(1.21±0.12)、(9.02±0.24)、(5.01±1.21)d优于对照组(2.42±0.34)、(11.23±1.51)、(2.24±0.25)、(12.23±1.78)、(7.42±2.21)d(t=8.281、9.195、8.224、9.183、8.772,P<0.05);治疗后观察组FEV1、FVC、左室收缩末期内径、左室射血分数(2.32±0.67)L、(3.25±0.66)L、(42.22±2.31)mm、(48.61±0.22)%优于对照组(1.68±0.21)L、(2.67±0.53)L、(55.48±2.11)mm、(42.28±0.31)%(t=7.822、8.021、7.421、5.011,P<0.05)。观察组用药不良反应3例(6.67%)和对照组2例(4.44%),差异无统计学意义(χ^2=0.2118,P>0.05)。结论常规治疗方案联合米力农治疗儿童肺炎并心力衰竭的疗效确切。

Objective To investigate the therapeutic effect of milrinone in the treatment of children with pneumonia and heart failure.Methods According to the random number table method,90 children with pneumonia and heart failure from January 2017 to February 2018 were convenient selected and divided into two groups.The control group was given a conventional treatment regimen,and the observation group was given a conventional treatment regimen in combination with milrinone.Compare the results.Results In the observation group,the outcome of treatment for children with pneumonia and heart failure was 44(97.78%),which was higher than that of the control group 31 cases(68.89%)(χ^2=13.520,P<0.05).The respiratory recovery time of the observation group,elimination of irritability time,heart rate stabilization time,lung disappearance time of the voice and the time of liver reduction were(1.43±0.21),(8.13±0.21),(1.21±0.12),(9.02±0.24),(5.01±1.21)d,which were better than the control group(2.42±0.34),(11.23±1.51),(2.24±0.25).(12.23±1.78)d(7.42±2.21)d,(t=8.281,9.195,8.224,9.183,8.772,P<0.05);after treatment,FEV1,FVC,left ventricular end-systolic diameter,left ventricular ejection fraction(2.32±0.67)L,(3.25±0.66)L,(42.22±2.31)mm,(48.61±0.22)%better than the control group(1.68±0.21)L,(2.67±0.53)L,(55.48±2.11)mm,(42.28±0.31)%(t=7.822,8.021,7.421,5.011,P<0.05).There was no significant difference between the adverse drug reaction 3 cases(6.67%)and the control group 2 cases(4.44%)in the observation group(χ^2=0.211 8,P>0.05).Conclusion The conventional treatment regimen combined with milrinone is effective in the treatment of children with pneumonia and heart failure.